BRR1 Antibody

What is the BACH1/BRIP1 protein and why is it important in research?

BACH1/BRIP1 functions as a DNA-dependent ATPase and 5'-3' DNA helicase that is critical for maintaining chromosomal stability. The protein plays essential roles in several DNA repair pathways, particularly in the repair of DNA double-strand breaks through homologous recombination. Its activity is dependent on its association with BRCA1, a well-established tumor suppressor protein . BRIP1 also acts downstream in the Fanconi anemia pathway following FANCD2 ubiquitination, making it a key player in cellular responses to DNA damage . The protein's ability to unwind G-quadruplex DNA structures and RNA:DNA substrates further emphasizes its importance in maintaining genomic integrity .

What are the common alternative designations for BR1/BRIP1 proteins?

The BACH1/BRIP1 protein is known by several alternative names in scientific literature, including FANCJ, Fanconi anemia group J protein, BRCA1-associated C-terminal helicase 1, BRCA1-interacting protein C-terminal helicase 1, and DNA 5'-3' helicase FANCJ . Understanding these alternate designations is critical when conducting literature searches or when examining experimental data across different research groups.

How does the NY-BR-1 antigen differ from BACH1/BRIP1?

NY-BR-1 is a breast cancer-associated differentiation antigen with intrinsic immunogenicity that can elicit endogenous T and B cell responses . Unlike BACH1/BRIP1, which functions in DNA repair pathways, NY-BR-1 serves as a tumor-associated antigen that can be targeted for immunotherapeutic approaches. Research models have been developed to investigate NY-BR-1-specific immune responses, particularly focusing on H2-Db-restricted CD8+ T cell epitopes and HLA-DR4-restricted T cell interactions .

What are the optimal conditions for using anti-BACH1/BRIP1 antibodies in immunoprecipitation experiments?

For immunoprecipitation of BACH1/BRIP1, researchers should use approximately 3 μg of antibody per mg of cell lysate. Based on published protocols, effective immunoprecipitation has been demonstrated using HeLa whole cell lysates (1mg) with the antibody, followed by Western blot analysis using a different detection antibody (1 μg/ml) . When optimizing your own protocol, maintain protein samples on ice during lysate preparation and consider using protease inhibitors to prevent degradation. The antibody's efficacy in pulling down the native protein complex suggests its suitability for studying protein-protein interactions involving BACH1/BRIP1 .

How can researchers establish a NY-BR-1 expressing tumor model for in vivo studies?

Establishing a NY-BR-1 expressing tumor model requires several methodological steps. First, select an appropriate murine mammary carcinoma cell line such as EO771 (of C57BL/6 origin, H2b) . Transfect these cells with a NY-BR-1 expression vector (e.g., pcDNA3.1(-) containing the NY-BR-1 encoding cDNA fragment) using standard transfection protocols. Following antibiotic selection (e.g., with Zeocin at 400 μg/mL), isolate individual clones by limiting dilution. Verify NY-BR-1 expression by Western blot using specific monoclonal antibodies. For in vivo studies, heterotopically transplant the stable transfectant clones into appropriate mouse models, such as HLA-DR4 transgenic mice if you wish to study both HLA-DR4-restricted CD4+ T cell responses and CTLs against NY-BR-1 expressing tumors .

What methods are most effective for validating BR1-specific T cell responses?

Multiple complementary approaches should be used to validate BR1-specific T cell responses. IFNγ ELISPOT assays can quantify the functional activity of T cells responding to BR1 epitopes. Use 5 μg/mL anti-mouse IFNγ capture antibody for membrane coating . Flow cytometry using fluorochrome-conjugated multimers (such as APC-labeled H2-Db dextramers loaded with BR1 peptides) can identify and enumerate antigen-specific CD8+ T cells. Include appropriate controls such as dextramers loaded with irrelevant peptides (e.g., HPV 16 E7 49-57) . For comprehensive phenotyping of tumor-infiltrating lymphocytes, analyze cells for markers including CD3, CD8, CD4, and CD14, with appropriate isotype controls at dilutions of 1:50-1:100 .

How do BR1 antibodies contribute to understanding the connection between periodontal disease and rheumatoid arthritis?

BR1 antibodies have emerged as important tools for investigating the mechanistic link between periodontal disease and rheumatoid arthritis. Research led by Dr. Gregory J. Tsay has identified specific peptide sections from Porphyromonas gingivalis, the major pathogen in periodontal disease, that may serve as diagnostic markers for rheumatoid arthritis . The pathogen produces toxic factors including gingipains with domains like RgpA (arginine gingipain) and Kpg (lysine gingipain) that may contribute to autoimmune reactions . An innovative serological test based on BR1 (Anti-BR1 IgG ELISA Kit) has been developed for clinical diagnosis, potentially addressing the limitations of traditional rheumatoid arthritis markers (RF and ACPA), which can be negative in up to 30% of patients .

What are the key considerations when interpreting MHC binding affinity data for BR1 epitopes?

When analyzing MHC binding affinity data for BR1 epitopes, researchers should consider several methodological aspects. Peptide binding assays are typically performed using RMA-S cells (2 × 105 cells) incubated overnight with graded peptide concentrations in round-bottom microtiter plates . The binding is then assessed via indirect immunofluorescence staining using hybridomas specific for MHC molecules (such as E3-25 or B22.249 for H2-Kb or H2-Db molecules, respectively) . When interpreting the data, consider the relative binding affinity compared to known high-affinity peptides, the stability of the peptide-MHC complex over time, and the potential influence of anchor residues. Remember that high binding affinity doesn't necessarily correlate with immunogenicity, as T cell receptor recognition adds another layer of specificity.

How can researchers overcome challenges in detecting low-abundance BRIP1 protein modifications?

Detecting low-abundance modifications of BRIP1 protein requires specialized approaches. Consider enrichment strategies prior to analysis, such as immunoprecipitation with antibodies specific to the BRIP1 protein or to the modification of interest (e.g., phospho-specific antibodies) . For Western blot detection, use enhanced chemiluminescence systems with extended exposure times or more sensitive detection methods such as CCD camera-based imaging rather than X-ray film . Consider using targeted mass spectrometry approaches like Selected Reaction Monitoring (SRM) or Parallel Reaction Monitoring (PRM) for quantitative analysis of specific BRIP1 modifications. When studying BRIP1's role in DNA repair pathways, synchronize cells and examine modification patterns following specific DNA-damaging treatments to enhance the signal of damage-induced modifications.

What strategies can resolve non-specific binding issues with anti-BRIP1 antibodies in complex tissue samples?

Non-specific binding with anti-BRIP1 antibodies can be minimized through several approaches. First, optimize blocking conditions by testing different blocking agents (BSA, non-fat milk, normal serum) at varying concentrations (0.5-5%) . For Western blots, 0.5% non-fat milk in TBS-T buffer has proven effective for BACH1/BRIP1 detection . Consider implementing more stringent washing steps, including increased washing duration and additional wash cycles. Pre-absorb the primary antibody with proteins from the species of the tissue sample to reduce cross-reactivity. Include appropriate negative controls such as isotype-matched irrelevant antibodies . For particularly challenging samples, consider using monovalent antibody fragments (Fab) instead of whole IgG to reduce Fc-mediated binding. Finally, validate specificity through complementary approaches such as RNA interference followed by immunoblotting.

How can researchers distinguish between true NY-BR-1 specific T cell responses and background reactivity?

To distinguish genuine NY-BR-1 specific T cell responses from background reactivity, implement multiple control conditions in your assays. In IFNγ ELISPOT or catch assays, include wells with T cells alone, T cells with irrelevant peptides, and T cells with relevant peptides but from non-immunized subjects . For dextramer staining, use parallel staining with dextramers loaded with irrelevant peptides (such as HPV epitopes) at the same concentration . Implement a rigorous gating strategy that includes viability dyes (such as LIVE/DEAD® Fixable Yellow Dead Cell Stain) and relevant T cell markers (CD3, CD8) . Calculate the signal-to-noise ratio by comparing epitope-specific responses to background. Statistical analysis methods such as the Mann Whitney test can help determine if differences between test and control conditions are significant . Consider including biological replicates and repeating experiments to confirm reproducibility of results.

What factors influence the performance of BR1-based diagnostic kits for rheumatoid arthritis?

Several factors can impact the performance of BR1-based diagnostic kits for rheumatoid arthritis. Sample quality is crucial—hemolyzed or lipemic samples may interfere with ELISA readings . Timing of sample collection relative to disease state and medication status can affect antibody titers. Technical factors during the ELISA procedure, including incubation times and temperatures, washing efficiency, and reagent quality, can all influence test results . When evaluating diagnostic performance, consider the sensitivity and specificity against established diagnosis criteria, and the potential complementarity with traditional markers like RF and ACPA . Finally, patient-specific factors including age, sex, smoking status, periodontal disease severity, and genetic background may all impact BR1 antibody levels and should be considered when interpreting results.

How might combined targeting of BRIP1 and BRCA1 pathways enhance therapeutic strategies for cancer?

Targeting the BRIP1-BRCA1 interaction represents a promising therapeutic approach, given their cooperative roles in DNA repair through homologous recombination . Researchers could develop small molecule inhibitors or peptide mimetics that disrupt this interaction, potentially sensitizing cancer cells to DNA-damaging agents. Since BRIP1 acts in the Fanconi anemia pathway after FANCD2 ubiquitination, combination therapies targeting multiple steps in this pathway might create synthetic lethality in certain cancer types . The helicase activity of BRIP1, particularly its role in unwinding G-quadruplex structures, offers another targetable function, as G-quadruplexes are enriched in oncogene promoters . Future research should explore the differential expression and mutation patterns of BRIP1 across cancer types to identify patients most likely to benefit from such therapeutic approaches.

What potential exists for NY-BR-1 as a target for breast cancer immunotherapy development?

NY-BR-1 shows considerable promise as an immunotherapeutic target for breast cancer. As a differentiation antigen with intrinsic immunogenicity, NY-BR-1 can elicit both T and B cell responses . The identification of specific H2-Db-restricted CD8+ T cell epitopes provides a foundation for developing targeted immunotherapies . Preclinical studies have demonstrated that immunization with recombinant adenoviruses expressing NY-BR-1 can provide partial protection against NY-BR-1 expressing tumors and enhance macrophage infiltration in tumor tissue . Future research should focus on identifying additional epitopes across diverse HLA types, exploring combination approaches with checkpoint inhibitors, and developing strategies to overcome potential immune evasion mechanisms. Clinical translation would benefit from better understanding the patterns of NY-BR-1 expression across breast cancer subtypes and stages.

How might advances in BR1 research contribute to novel therapeutic approaches for autoimmune disorders beyond rheumatoid arthritis?

Research on BR1 in rheumatoid arthritis could extend to other autoimmune conditions with similar pathogenic mechanisms. The connection between periodontal pathogens and autoimmunity suggests potential applications in conditions like psoriatic arthritis, ankylosing spondylitis, or systemic lupus erythematosus . Future investigations should explore cross-reactivity of BR1 antibodies with self-antigens in various tissues, potentially revealing molecular mimicry mechanisms in other autoimmune disorders. Therapeutic approaches might include targeted antimicrobial strategies against P. gingivalis, peptide-based immunomodulation targeting specific BR1 epitopes, or development of small molecules that block pathogenic interactions between BR1 and host proteins . The BR1 diagnostic approach could also be adapted to develop biomarker panels for early detection or monitoring of treatment response in multiple autoimmune conditions.